Stock Analysis, Dividends, Split History

WMIH / WMIH Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)314.16
Enterprise Value ($M)285.11
Book Value ($M)85.99
Book Value / Share0.40
Price / Book3.65
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 206,714,132
Common Stock Shares Outstanding 206,714,132
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.28
Return on Assets (ROA)0.04
Return on Equity (ROE)0.13
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Operating Income-2.48
Net Income25.88
Earnings Per Share Basic0.01
Earnings Per Share Diluted0.01
Cash Flow Statement (mra) ($M)
Cash From Operations-6.42
Cash from Investing73.05
Cash from Financing-6.42
Identifiers and Descriptors
Central Index Key (CIK)933136
Industry Groups

Split History

Stock splits are used by WMIH Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
WMIH : WMIH Corporation Stock Analysis and Research Report

2017-10-15 - Asif

WMIH Corp. (“WMIH”) is a corporation duly organized and existing under the laws of the State of Delaware. On May 11, 2015, WMIH merged with its parent corporation, WMI Holdings Corp., a Washington corporation (“WMIHC”), with WMIH as the surviving corporation in the merger (the “Merger”). The Merger occurred as part of the reincorporation of WMIHC from the State of Washington to the State of Delaware effective May 11, 2015 (the “Reincorporation Date”). WMIH, formerly known as WMIHC and Washington Mutual, Inc. (“WMI”), is the direct parent of WM Mortgage Reinsurance Company, Inc. (“WMMRC”) and WMI Investment Corp. (“WMIIC”) which has no assets or liabilities. Since emergence from bankruptcy on March 19, 2012 (the “Effective Date”), The company had limited operations other than WMMRC’s legacy reinsurance business, which is being operated in runoff mode. The company continue to operate WMMRC’s business in runoff mode and its primary strategic objective is to consummate one or more ac...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Tracking David Tepper's Appaloosa Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018. (125-9)

5 Analyst Stock Picks Under $10 Given Massive Upside Targets

2018-08-25 247wallst
Investors have gone through a lot in 2018, seeing much more volatility but also seeing the stock market hit all-time highs. The market’s bottom was almost 10 years ago, and the bull market is now the longest running on record. Now investors are looking for new ideas on how to position their assets and holdings for the coming months and beyond. (46-11)

Top Analyst Upgrades and Downgrades: Alibaba, Altria, Autodesk, Hormel, HP, Netflix, Tandem Diabetes, Turtle Beach and More

2018-08-24 247wallst
Stocks were indicated to open higher after a very mixed week of trading, but all ears will be on Federal Reserve Chair Powell speaking in Jackson Hole on Friday for any comments about the interest rate outlook. Despite the strong earnings season being all but over and despite the all-time highs in the S&P 500 this week, investors have seen less reward in 2018 in buying every dip than they had been used to in recent years. (63-6)

Stocks To Watch: More Trade Tiffs And Stress Tests

2018-06-23 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Trade battles are set to dominate another week's action, with a set of hair-trigger responses from former trade allies leading world news though threatened tariffs are still small in the face of a $20T U. (1297-2)

Impac Board And C-Suite Completely Overhauled Ahead Of Sale?

2018-06-05 seekingalpha
Subtracting out liabilities, the company could be acquired for more than double the current market price. (121-1)

CUSIP: 92936P100